Cofttek holdings limited

CDK&Aurora kinase

ML167 (1285702-20-6)

ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B

Not Intended for Therapeutic Use. For research use only.

CAS: 1285702-20-6 Category

ML167 (1285702-20-6) Description

ML167 is the first highly selective inhibitor of of Cdc2-like kinase 4 (Clk4) with an IC50 of 136 nM for Clk4. The Cdc2-like kinases (ClkÂ’s) and the dual-specificity tyrosine phosphorylation-regulated kinases (DyrkÂ’s) have specified roles in gene splicing. Specifically, the Clk class of enzymes has been shown to phosphorylate the serine- and arginine-rich (SR) proteins, which are a major component of the spliceosome.

 

ML167 (1285702-20-6) Specifications

Product Name ML167
Synonyms ML167; ML-167; ML 167; CID 44968231; CID44968231; CID-44968231; NCGC00188654; NCGC-00188654; NCGC 00188654
Chemical Names (5-(4-(((5-methylfuran-2-yl)methyl)amino)quinazolin-6-yl)furan-2-yl)methanol
Purity ≥98% (HPLC)
CAS Number  1285702-20-6
Molecular Formula C19H17N3O3
Molecular Weight 335.35658
Monoisotopic Mass 335.12699 g/mol
MDL number MFCD27978379
InChIKey ROCFOIBAEVAOLQ-UHFFFAOYSA-N
InChi Code  InChI=1S/C19H17N3O3/c1-12-2-4-14(24-12)9-20-19-16-8-13(3-6-17(16)21-11-22-19)18-7-5-15(10-23)25-18/h2-8,11,23H,9-10H2,1H3,(H,20,21,22)
SMILES OCC1=CC=C(C2=CC3=C(NCC4=CC=C(C)O4)N=CN=C3C=C2)O1
Form Powder
Color off-white to gray to brown
Solubility  Soluble in DMSO: soluble10mg/mL, clear
Storage Temp.  −20°C
Shelf life >2 years if stored properly
Handling Protect from air and light
Application A highly selective Cdc2-like kinase 4 (Clk4) inhibitor

 


=

RIDADR NONH for all modes of transport

References:

[1]. Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, Misteli T, Auld DS, Maloney DJ, Thomas CJ. An inhibitor of the Cdc2-like kinase 4 (Clk4). 2010 Mar 29 [updated 2011 Mar 3]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK56236/ PubMed PMID: 21735605.

[2]. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.Panicker PS, Melge AR, Biswas L, Keechilat P, Mohan CG.Chem Biol Drug Des. 2017 Oct;90(4):629-636. doi: 10.1111/cbdd.12977. Epub 2017 May 3.PMID: 28303669

[3].An inhibitor of the Cdc2-like kinase 4 (Clk4).Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, Misteli T, Auld DS, Maloney DJ, Thomas CJ.Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.2010 Mar 29 [updated 2011 Mar 3].PMID: 21735605